Next-generation sequencing (NGS) of tumors in patients with advanced non–small cell lung cancer (NSCLC) is now a standard of care that informs the clinician on the best therapeutic approach for their patients. In fact, for advanced NSCLC, the current National Comprehensive Cancer Network recommendations advocate NGS testing before initiation of first-line therapy.
NGS can analyze targeted DNA locations, the whole exome, or the whole genome in a single test; therefore, it has established itself as one of the tests at the forefront of precision medicine because it can identify patients who are candidates for targeted therapy.
The following oncogenic drivers may be tested in NSCLC: Kirsten rat sarcoma (KRAS), epidermal growth factor receptor (EGFR), MET, anaplastic lymphoma kinase (ALK), c-ROS oncogene 1, v-raf murine sarcoma viral oncogene homolog B (BRAF), neurotrophic receptor tyrosine kinase (NTRK), human epidermal growth factor 2 (HER2), neuregulin-1 (NRG1), and rearranged during transfection (RET). Also, immune checkpoint inhibitor biomarkers (programmed death-ligand 1) should be checked.
How much do you know about NGS in NSCLC? Test your knowledge with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer - Medscape - Aug 22, 2022.